Empowered Funds LLC Makes New $1.31 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Empowered Funds LLC purchased a new position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 4,355 shares of the biopharmaceutical company’s stock, valued at approximately $1,311,000.

Other institutional investors also recently bought and sold shares of the company. MV Capital Management Inc. purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at about $25,000. HM Payson & Co. purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth $27,000. Golden State Wealth Management LLC raised its stake in Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 36 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in shares of Alnylam Pharmaceuticals in the third quarter worth about $29,000. Finally, Manchester Capital Management LLC boosted its position in shares of Alnylam Pharmaceuticals by 600.0% during the fourth quarter. Manchester Capital Management LLC now owns 84 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 72 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $266.11 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $197.81 and a one year high of $495.55. The stock has a market cap of $35.61 billion, a PE ratio of 49.46 and a beta of 0.31. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.99 and a current ratio of 3.05. The stock has a 50 day moving average price of $259.25 and a 200 day moving average price of $291.61.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company had revenue of $1.29 billion during the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the prior year, the business earned ($0.51) EPS. The firm’s quarterly revenue was up 66.9% on a year-over-year basis. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.59 EPS for the current fiscal year.

Analyst Ratings Changes

ALNY has been the topic of a number of research reports. Bank of America reduced their target price on shares of Alnylam Pharmaceuticals from $460.00 to $410.00 and set a “buy” rating on the stock in a report on Tuesday, July 14th. Truist Financial reduced their price target on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a research report on Tuesday, August 4th. Citigroup lowered their target price on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Sanford C. Bernstein restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday. Finally, Wells Fargo & Company reduced their target price on Alnylam Pharmaceuticals from $316.00 to $256.00 and set an “equal weight” rating for the company in a research note on Friday, August 14th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $386.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.